Immunology and Bi...
Follow
Find
4.7K views | +3 today
 
Scooped by Gilbert Faure au nom de l'ASSIM
onto Immunology and Biotherapies
Scoop.it!

Cancer Immunology at Dana-Farber | Insight

Cancer Immunology at Dana-Farber | Insight | Immunology and Biotherapies | Scoop.it
The mission of the CVC is to translate the promising insights from basic immunology into therapeutics that benefit cancer patients. The CVC undertook a series of clinical trials exploring the biologic activity of autologous tumor ...
more...
No comment yet.
Immunology and Biotherapies
Page Ressources et Actualités du DIU immunologie et biothérapies
Your new post is loading...
Your new post is loading...
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Resources for DIU Immunologie et Biothérapies

DIU Immunologie et Biotherapies is a french diploma associating many french universities and immunology laboratories. It is dedicated to the involvement of immunology in new biotherapies, either molecular or cellular

Gilbert Faure au nom de l'ASSIM's insight:

We choose Scoop.it as the best curation tool to collect, select, comment informations flowing on the web in this rapidly evolving theme to keep teachers abreast of scientific knowledge and help students surf the wave...

Feel free to be a follower!

 

If you are interested

in Immunology also use http://www.scoop.it/t/immunology

in Mucosal Immunity http://www.scoop.it/t/mucosal-immunity

in Flow Cytometry and Cytomics http://www.scoop.it/t/from-flow-cytometry-to-cytomics

in Allergy an Clinical Immunology http://www.scoop.it/t/allergy-and-clinical-immunology

in Autoimmunity http://www.scoop.it/t/autoimmunity

 

For further informantions on Immune monitoring of Immune therapies, go to

http://www.scoop.it/t/immune-monitoring-1

by MdC

 

Looking for cancer applications inside this topic, use

http://www.scoop.it/t/immunology-and-biotherapies?q=cancer

 

Looking for cytokines and chemokines, use

http://www.scoop.it/t/cytokines-et-chimiokines

 

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Stem Cell Therapies Hold Promise, But Obstacles Remain - University of Rochester Newsroom

Stem Cell Therapies Hold Promise, But Obstacles Remain - University of Rochester Newsroom | Immunology and Biotherapies | Scoop.it
University of Rochester Newsroom Stem Cell Therapies Hold Promise, But Obstacles Remain University of Rochester Newsroom In an article appearing online today in the journal Science, a group of researchers, including University of Rochester...
Gilbert Faure au nom de l'ASSIM's insight:

The review article focuses on pluripotent stem cells (PSCs), which are stem cells that can give rise to all cell types. These include both embryonic stem cells, and those derived from mature cells that have been “reprogrammed” or “induced” – a process typically involving a patient’s own skin cells – so that they possess the characteristics of stem cells found at the earliest stage of development.

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

FDA Receives First-Ever Biosimilar Application for Monoclonal Antibody - Regulatory Focus

FDA Receives First-Ever Biosimilar Application for Monoclonal Antibody - Regulatory Focus | Immunology and Biotherapies | Scoop.it
Regulatory Focus FDA Receives First-Ever Biosimilar Application for Monoclonal Antibody Regulatory Focus The company's biosimilar filing is the second-ever filing of a drug through FDA's new 351(k) biosimilar pathway, and reportedly the first-ever...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Plant derived monoclonal antibodies vs HIV-1 – erv - ScienceBlogs

Plant derived monoclonal antibodies vs HIV-1 – erv - ScienceBlogs | Immunology and Biotherapies | Scoop.it
About 15 years ago, it was thought that genetically engineered crops would be widely used to produce human proteins for use as drugs. When Dr. Whaley and Dr. Zeitlin (the scientists behind the anti-Ebola therapy currently in ...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

ZMapp | WikiWand

ZMapp | WikiWand | Immunology and Biotherapies | Scoop.it
ZMapp is an experimental biopharmaceutical drug comprising three humanized monoclonal antibodies under development as a treatment for Ebola virus disease.[1] The drug was first tested in humans during the 2014 West Africa Ebola virus outbreak.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Physician Groups Side With Big Drug Makers Over Biosimilar Names - Wall Street Journal (blog)

Physician Groups Side With Big Drug Makers Over Biosimilar Names - Wall Street Journal (blog) | Immunology and Biotherapies | Scoop.it
Physician Groups Side With Big Drug Makers Over Biosimilar Names Wall Street Journal (blog) Among the groups that signed the letter: the American Academy of Asthma Allergy and Immunology; the American Academy of Clinical Endocrinologists; the...
Gilbert Faure au nom de l'ASSIM's insight:

The latest missive was sent by 10 medical societies and a physicians’ group, which want the agency to require biosimilars to have distinct names from brand-name biologics. Why? The doctors believe different names will make it easier for prescribers to distinguish between medicines that “may differ slightly” and also track adverse events and side effect reports that appear in patient records.

“The question of whether a follow-on product [or biosimilar] will share a non-proprietary name with a [brand-name biologic] is critical,” the groups wrote yesterday in their letter to FDA Commissioner Margaret Hamburg.

The name game has become a controversial public policy issue. That’s because biosimilars, which are not yet available in the U.S., are designed to emulate brand-name biologics and are forecast to save untold billions of dollars in health care costs in coming years. A key point of contention is whether different names would hamper substitution needed for lowering health care costs.

Brand-name drug makers and biotechs want biosimilars to have unique or generic names to distinguish the medicines, and they cite the same reasons as the medical societies. Of course, a distinct name also gives these companies a marketing advantage. By requiring biosimilars to have different names, product substitution may become more difficult.

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection - The Cochrane Library - Li - Wiley Online Library

RT @infdisease_news: Humanized PA14 (A Monoclonal CCR5 Antibody) for Treatment of People with #HIV Infection http://t.co/7qNusn7VqJ
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Top Selling Monoclonal Antibodies 2013
Scoop.it!

Producing Vaccines, biologics and monoclonal antibodies from Plants. Medicago

Producing Vaccines, biologics and monoclonal antibodies from Plants. Medicago | Immunology and Biotherapies | Scoop.it

 

 Why VLPs? For effective, long-lasting vaccines

Virus-Like Particles (VLPs) represent one of the most exciting emerging vaccine technologies for generating effective and long-lasting protection. VLPs consist of  protein shells studded with short strands of the proteins specific to whatever disease the vaccine is intended to control. VLPs are made to look like a virus, allowing them to be recognized readily by the body's immune system, however, they lack the core genetic material, making them non-infectious and unable to replicate. Unlike current influenza vaccines that are manufactured with an inactivated virus, VLP-based vaccines do no require an actual sample of the virus, they simply require the genetic sequence of the virus or bacteria. 

Another important advantage of VLPs is that they more effectively activate key aspects of the immune response to achieve potent immune stimulation and to provide immunological memory. VLP-based vaccines have also shown to provide protection against different strains of a virus other than those for which the vaccine was formulated. With influenza viruses mutating rapidly, the previous years vaccines produced in eggs often cannot be used. Medicago's VLP technology enables the creation of a vaccine that exactly matches the specific pandemic strain in circulation and offers strong cross-protection against other subtypes of influenza.

 

Medicago’s transient expression manufacturing platform, Proficia™, has been developed and optimized for use with Nicotiana benthamiana – a relative of the tobacco plant. The leaves of these plants are well suited to rapidly incorporate, in a non-permanent fashion, the genetic information required to produce high yields of VLPs. Thanks to the extensive experience accumulated on tobacco cultivation, scale-up and maintenance costs are relatively low. Furthermore, because fully grown plants are used, no potentially time-consuming crop development steps are necessary. By using plants in general, costs associated with infrastructure and raw materials are lower, and the risk of viral contaminants from animal sources is substantially reduced.
We have also developed a technology for the production of recombinant proteins in transgenic alfalfa. Transgenic alfalfa is best suited for the production of recombinant proteins required in high volumes and for which a relatively long lead time – up to six months – is not an issue. While this technology is not suited for the production of vaccines, we believe it may have applications in other fields of interest such as the production of biosimilars.

  


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, August 17, 4:10 AM

 Companies and academic labs are pursuing it to create medicines and vaccines against such targets as HIV, cancer, the deadly Marburg virus and norovirus, known for causing outbreaks of stomach bug on cruise ships, as well as Ebola.

 

ELELYSO is the first FDA-approved, plant cell-based ERT indicated for the treatment of Type 1 Gaucher disease.  It was developed by Israel  company Protalix and licensed to Pfizer.

 

ELELYSO™ (taliglucerase alfa, Pfizer) for injection is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for adults with a confirmed diagnosis of Type 1 Gaucher disease and was approved by the United States (U.S.) Food and Drug Administration (FDA) on May 1, 2012.

 

ZMAPP the Ebola mab is produced in Tobacco plants by MAPP Pharma.

 

 

 

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

The roles of myeloid-derived suppressor cells in transplantation, Expert Review of Clinical Immunology, Informa Healthcare

The roles of myeloid-derived suppressor cells in transplantation, Expert Review of Clinical Immunology, Informa Healthcare | Immunology and Biotherapies | Scoop.it
The roles of myeloid-derived suppressor cells in transplantation: Expert Review of Clinical Immunology, Ahead ... http://t.co/i1KayZceW2
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

AbbVie’s glioblastoma multiforme therapy receives orphan drug designation - Pharmaceutical Technology

AbbVie has obtained orphan drug designation from the European Medicines Agency (EMA) and the US FDA for its anti-epidermal growth factor receptor monoclonal antibody drug conjugate, ABT-414, as a treatment for glioblastoma multiforme.AbbVie...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Biologics in development

RT @TheStemCell: 2013 PhRMA biologics report. Of 79 #FDA cell therapy trials 48 are #stemcell (16 Ph1; 27 Ph2; 5 Ph3) http://t.co/slxXbcZ82J
Gilbert Faure au nom de l'ASSIM's insight:
2013REPORTAmerica’s biopharmaceutical researchcompanies are developing 907 biologicstargeting more than 100 diseases. Biologicsare developed through biological processesusing living cells or organisms.This report lists biologics in humanclinical trials or under review by theU.S. Food and Drug Administration(FDA). A link to the sponsor company’sweb site provides more detailed infor-mation on the science and technologiesbehind each potential product. The 907medicines and vaccines in developmentinclude:•338 cancer therapeutics that targetseveral different types of solid tumors,leukemia and lymphoma. Monoclonalantibodies account for 170 of the 338products in development.•176 candidates in development for anarray of infectious diseases, including134 vaccines.•71 medicines for autoimmune diseases,such as lupus, multiple sclerosis andrheumatoid arthritis.•58 treatments for cardiovasculardiseases, such as congestive heartfailure and stroke.•Other diseases include diabetes,digestive disorders, genetic disorders,

 

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

HIV Vaccine Trial Exploits a Dual and Central Role f... [J Virol. 2014] - PubMed - NCBI

PubMed comprises more than 23 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Loss of Cytotoxicity and Gain of Cytokine Production in Murine Tumor-Activated NK Cells

Loss of Cytotoxicity and Gain of Cytokine Production in Murine Tumor-Activated NK Cells | Immunology and Biotherapies | Scoop.it
by Jürgen R. Müller, Thomas A. Waldmann, Sigrid Dubois
NK cells are able to form a functional memory suggesting that some NK cells are surviving the activation process.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Drug saves monkeys with Marburg fever - Independent Online

Drug saves monkeys with Marburg fever - Independent Online | Immunology and Biotherapies | Scoop.it
Independent Online Drug saves monkeys with Marburg fever Independent Online Outside experts, while praising the Marburg study as an important advance, also expressed caution given its small size and the problematic safety history of this class of...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Hemoptysis and Acute Respiratory Syndrome (ARDS) as Delayed-Type Hypersensitivity After FOLFOX4 Plus Bevacizumab Treatment

Hemoptysis and Acute Respiratory Syndrome (ARDS) as Delayed-Type Hypersensitivity After FOLFOX4 Plus Bevacizumab Treatment | Immunology and Biotherapies | Scoop.it
Article Citation: Takaaki Kobayashi, Tadahiko Masaki, Koji Kogawa, Hiroyoshi Matsuoka, and Masanori Sugiyama (2013) Hemoptysis and Acute Respiratory Syndrome (ARDS) as Delayed-Type Hypersensitivity After FOLFOX4 Plus Bevacizumab Treatment.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Hematology
Scoop.it!

Natural (born) killer cells battle pediatric leukemia - EurekAlert (press release)

Natural (born) killer cells battle pediatric leukemia - EurekAlert (press release) | Immunology and Biotherapies | Scoop.it
Science Codex Natural (born) killer cells battle pediatric leukemia EurekAlert (press release) Researchers at Children's Hospital Los Angeles have shown that a select team of immune-system cells from patients with leukemia can be multiplied in the...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Intravenous Immunoglobulin for Hypogammaglobulinemia after Lung Transplantation: A Randomized Crossover Trial

Intravenous Immunoglobulin for Hypogammaglobulinemia after Lung Transplantation: A Randomized Crossover Trial | Immunology and Biotherapies | Scoop.it
by David J. Lederer, Nisha Philip, Debbie Rybak, Selim M. Arcasoy, Steven M.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal ... - Wall Street Journal

Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal ... - Wall Street Journal | Immunology and Biotherapies | Scoop.it
Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal ...
Gilbert Faure au nom de l'ASSIM's insight:

Moab for whooping cough

more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

A monoclonal antibody targeting neuropilin-1 inhibits adhesi... : Anti-Cancer Drugs

A monoclonal antibody targeting neuropilin-1 inhibits adhesi... : Anti-Cancer Drugs | Immunology and Biotherapies | Scoop.it
Neuropilin-1 (NRP-1) is a nontyrosine kinase coreceptor for semaphorin 3A and the vascular endothelial growth factor involved in tumor angiogenesis, growth, and metastasis and is regarded as a promising target for cancer therapy.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Access : Immunogenicity of Biotherapy Used in Psoriasis: The Science Behind the Scenes : Journal of Investigative Dermatology

The Journal of Investigative Dermatology publishes basic and clinical research in cutaneous biology and skin disease.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

19th century advances paved way for today's Ebola treatment - Boston Globe

19th century advances paved way for today's Ebola treatment - Boston Globe | Immunology and Biotherapies | Scoop.it
Boston Globe 19th century advances paved way for today's Ebola treatment Boston Globe The antibody treatment given to two American missionaries infected with the Ebola virus may seem like a modern day miracle cure, but researchers created similar,...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

CSL lifts profit on demand for plasma therapies - Sydney Morning Herald

CSL lifts profit on demand for plasma therapies - Sydney Morning Herald | Immunology and Biotherapies | Scoop.it
Sydney Morning Herald CSL lifts profit on demand for plasma therapies Sydney Morning Herald CSL chief executive Paul Perreault says the blood product and vaccine maker is better placed than its competitors to benefit from rising demand in China...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Anti-EphA3 antibody has anti-tumour effects against solid cancers

Anti-EphA3 antibody has anti-tumour effects against solid cancers | Immunology and Biotherapies | Scoop.it
An international team of scientists has shown that an antibody against the protein EphA3, found in the micro-environment of solid cancers, has anti-tumour effects.
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM from Cancer Immunotherapy Review
Scoop.it!

Addressing Dendritic Cells for Anticancer Immunity

Addressing Dendritic Cells for Anticancer Immunity | Immunology and Biotherapies | Scoop.it
August 15, 2014 | Lutz Nuhn, PhD | Institute of Organic Chemistry, Johannes Gutenberg-University, Duesbergweg 10-14, D-55099 Mainz (Germany)…

 

The comparison of antibody-polymer conjugates of different topologies (“cross-linked” versus “star-like”) demonstrated that the well-defined constructs derived from maleimide-endgroup modified HPMA copolymers prevent non-specific interaction with immune cells and guarantee antibody-mediated active delivery to the target cell type. By using aDEC205 as antibody the delivery of multifunctionalizable HPMA carrier polymers to CD8+ dendritic cells is possible enabling novel application especially for immontherapeutic purposes. [5] Considering the numerous possibilities of equipping the HPMA carriers with further tumor relevant antigens and immunostimulants, as recently shown by ligation of selective MUC1-derived glycopeptides antigens to HPMA block copolymers, [3] a combination with aDEC205 mediated delivery would guarantee antigen cross-presentation to CD8+ T cells and differentiation into specific cytotoxic T cells (CTLs) for selective antitumor response on a cellular level. As a result, such well-defined multifunctional HPMA-aDEC205 polymer conjugates can be considered as novel vaccine delivery platform towards antitumor immunity.


Via Krishan Maggon
more...
Krishan Maggon 's curator insight, August 16, 5:09 AM

open access

 

Addressing Dendritic Cells for Anticancer Immunity

August 15, 2014 | Lutz Nuhn, PhD | Institute of Organic Chemistry, Johannes Gutenberg-University, Duesbergweg 10-14, D-55099 Mainz (Germany) | doi 10.14229/jadc.2014.8.15.002

Received August 5, 2014 | Accepted August 11, 2014 | Published online August 15, 2014

 

Keywords:
ADC; Antibody-drug Conjugates; drug delivery; HPMA copolymers; polymer micelles; dendritic cells; DC; cancer immunotherapy

 

Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

Experimental chikungunya vaccine induces robust antibody response - National Institutes of Health (press release)

Experimental chikungunya vaccine induces robust antibody response - National Institutes of Health (press release) | Immunology and Biotherapies | Scoop.it
National Institutes of Health (press release) Experimental chikungunya vaccine induces robust antibody response National Institutes of Health (press release) An experimental vaccine to prevent the mosquito-borne viral illness chikungunya elicited...
more...
No comment yet.
Scooped by Gilbert Faure au nom de l'ASSIM
Scoop.it!

GEN | News Highlights:Ebola Serum Turns Out to Be an Antibody Cocktail

GEN | News Highlights:Ebola Serum Turns Out to Be an Antibody Cocktail | Immunology and Biotherapies | Scoop.it
The “secret serum” being used to treat the two Americans infected with Ebola virus is a three-monoclonal-antibody experimental cocktail provided by Mapp Biopharmaceutical.
more...
No comment yet.